813
Participants
Start Date
September 30, 2006
Primary Completion Date
June 30, 2008
Study Completion Date
June 30, 2008
Moxifloxacin (Avelox, BAY12-8039)
Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
Dublin
Dublin
Riga
Riga
Budapest
Bruxelles - Brussel
Vienna
Bruxelles - Brussel
Sofia
Sofia
Sofia
Johannesburg
Edegem
Bornem
Debrecen
Pleven
Worcester
Rousse
Kaposvár
Cape Town
Cape Town
Cape Town
Székesfehérvár
Graz
Graz
Veszprém
Győr
Dobrich
Vilnius
Athens
Milan
Hamburg
Lübeck
Pavia
Madrid
Madrid
Madrid
Quimper
Le Grau-du-Roi
Hanover
Haifa
Oviedo
Salamanca
Grenoble
Magdeburg
Bochum
Münster
Tel Litwinsky
Siena
Mainz
Nevers
Denain
Tourcoing
Boulogne-sur-Mer
Darmstadt
Odesa
Wiesbaden
Chieti
Mannheim
Annecy
Ivano-Frankivsk
Lviv
München
Avignon
Uzhhorod
Moscow
Moscow
Moscow
Moscow
Moscow
Yaroslavl
Moscow
Saint Petersburg
Smolensk
Cluj-Napoca
Iași
Athens
Athens
Athens
Rio Patras
Thessaloniki
Wilton
Galway
Sligo
Saint Petersburg
Dublin
Roma
Daugavpils
Liepāja
Riga
Valmiera
Kaunas
Šiauliai
Ukmerge
Alkmaar
Eindhoven
Krakow
Lublin
Lublin
Lublin
Poznan
Puławy
Warsaw
Bucharest
Bucharest
Bucharest
Pretoria
Barcelona
Barcelona
Terrassa (Barcelona)
Kiev
Kiev
Kiev
Kiev
London
Winchester
Inverness
Edinburgh
Manchester
Glasgow
Newcastle upon Tyne
Leeds
York
Lead Sponsor
Bayer
INDUSTRY